Turkey: Generic Vs. Innovator, Damages Action, Second Civil Court Of Intellectual And Industrial Property Rights In Istanbul, 1111/222 E. (2222/333 E.), 20 September 2013

Last Updated: 15 July 2019
Article by Selin Sinem Erciyas, Aysel Korkmaz Yatkın and Aysu Eryaşar


The Turkish Court of first instance held that the liability for damages arising from an unfair preliminary injunction (where no infringement was found in the action on the merits) is a type of strict liability and therefore did not investigate whether the defendant was at fault when ruling that the conditions for compensation were deemed to be fulfilled. The decision given in this case is the first known decision in Turkey for the compensation of damages arising from an unfair preliminary injunction decision in the pharmaceutical industry, and may therefore establish an important precedent.


Facts of the case

The defendant companies requested a preliminary injunction be granted due to the imminent danger of infringement of the patent by the Claimant (a local pharmaceutical company)'s generic product. The court granted the PI and decided to suspend the manufacture of the Gx products, pending the outcome of a court-appointed expert panel's report.

The defendant then filed an infringement action on the merits and the PI was maintained throughout the proceedings. Within the scope of the action on the merits, a new expert examination was conducted which found no patent infringement. Due to the conflicting expert reports, the Court lifted the PI. Ultimately, the infringement action on the merits was rejected and the decision became final following the Appeal process.

The claimant then filed an action claiming compensation for damages, alleging that it had incurred a loss of profits due to not being able to manufacture the Gx products due to the unfair PI.

Question in Dispute

Was the rejection of the action on the merits sufficient to claim compensation for damages due to the preliminary injunction? If a pharmaceutical company did not put the Gx product on the market even after the preliminary injunction decision had been lifted, can it still demand compensation on the ground that it was unfairly prevented from manufacture and marketing of the Gx products; if yes, on what basis should the loss of profit/damages be calculated for a pharmaceutical product that was never put on the market?

Arguments of the Parties

The plaintiff mainly argued that it was prevented from manufacturing and marketing its Gx products due to the unfair PI and that had it not been prevented as such, it would have been the first Gx on the market and 85% of the market share of the patented pharmaceutical would have automatically shifted to the plaintiff company. It also argued that liability to compensate for damage caused by the preliminary injunction was subject to strict liability provisions, so the defendant did not need to be at fault in order to pay the compensation. For this reason, it claimed 85% of the sales of the defendant during the entire period of the preliminary injunction as compensation. Based on these arguments, the plaintiff asked the Court to order the defendant to pay the amount of TL 4,500,000 (approximately EUR 750,000) as compensation for its damages due to the unfair PI.

The defendant firstly stated that the casual link between the damage alleged by the plaintiff and the fault could not be proven, and more importantly the Gx product was never put on the market even after the PI was lifted. Therefore the damages demand should be rejected. In relation to the alleged damages, the defendant pointed out that at the date of the PI the Gx product only had a marketing authorization, which is not sufficient to launch the product. The regulatory steps that need to be completed (price approval, sales permission etc) had been taken by the plaintiff at a later stage and it took 125 days for the plaintiff to complete these steps and become ready for launch. Therefore, the aforementioned 125 days had to be deducted from the term of the PI when calculating the damages. The defendant further emphasized that the Gx product had only been approved for a single indication while the original product had two different indications. Consequently, the market share of the original product with two indications would naturally be higher than the market share of the Gx. The Court should take the approved indication's market share only. The defendant further stated that in any case it could not be assumed that the Gx would automatically take over the whole market share of the originator. Especially in the area of oncology drugs, the trust in the original product and the originator company makes physicians and patients less inclined to switch to the Gx. This is especially true when it is considered that the plaintiff has changed the formulation of its drug in question five times. Finally, the defendant provided the Court with the official data which indicated the market share of the first Gx to enter the market with a very similar oncology drug. The market share of the Gx was between 6% to 16% and the Gx company in that case was a very well-known and reputable one, unlike the Gx company in the current action. Finally, in relation to the calculation of loss of profit of the plaintiff, the defendant emphasized that the first price approved by the Ministry of Health could not be taken into consideration because there has to be mandatory and arbitrary discounts on the pharmaceutical prices until they reach an end price. Besides, the court should also calculate the expenses of the Gx company as well in order to ascertain the profit it could have had if there was no PI.

Judgment of the Court

The court of first instance (Istanbul 2nd Court of Intellectual and Industrial Property Rights) ruled that in order to be held liable for compensation for damages incurred due to the preliminary injunction decision, it was sufficient that the main case (here the infringement case) was rejected and that there was no need to investigate whether the defendant was at fault.

For the calculation of the damages, the Court deducted 17 days from the term of the PI as being the period necessary to have the sales permission granted. Then, the Court took the example provided by the defendant (indicating that the market share of a similar oncology Gx product as the first Gx on the market was between 6-16%) and decided that the market share of the plaintiff would have been 16% if the PI had not been granted, without considering the fact that the Gx was approved only for one indication whereas the original product had two indications. Finally, the Court took the first price (the highest price) approved by the Ministry of Health, which would certainly not be the sales price of the Gx product, due at the least to legal mandatory discounts applied to pharmaceuticals in Turkey.

Finally, the Court ordered the amount of TL 2,000,000 (approximately EUR 330,000) to be paid to plaintiff company as compensation for its damages due to the unfair PI.

Both parties appealed the decision. At the time of writing, the file was still pending before the District Court.


The essential issue in this case was the calculation of loss of profit of a Gx company which had never launched its product on the market. The market share, the price and the possible expenses of the Gx company had to be calculated in order to ascertain what would have been the profit of the Gx company if it could have launched during the term of the PI. In order to visualize this scenario in as concrete a way as possible, both parties came up with suggested solutions serving their own interest. However it is important to note that the plaintiff did not bring any evidence indicating that it would have been able to sell its Gx product at the highest price granted by the Ministry of Health and that it would have possessed 85% of the market. The only ground relied on by the Gx company was the argumentation of the patentee brought during the PI proceedings that there was a risk of the patented product losing 85% of its market share if the Gx launched. This was the only argumentation of the plaintiff Gx company that it would "objectively" possess 85% of the market. As the plaintiff never launched its Gx products, it also relied on the sales figures and market shares of the actual first Gx entered onto the market; as if whatever the figures say for the actual first Gx would be identical for the plaintiff's product. The IP Court rejected all these arguments on the counter arguments brought by the defendant, stating that the market conditions at the date of the preliminary injunction decision, the legal regulations on the market at that time, the reputation and reliability of the Gx company and the sector where the product will enter the market for the first time are of great importance in the calculation of the market share.

In addition, the court ignored a very important issue: the mandatory discount rates to be made on the first price of the Gx product. Accordingly, the alleged loss of profit cannot be calculated as if the Gx company would be able to sell its products at the highest price approved by the Ministry of Health.

It is also noteworthy that the Court considered liability to compensate the damage caused by the preliminary injunction to be one of the strict liability cases, despite the fact that the strict liability cases are counted as numerous clauses within the Turkish law and the liability to compensate damage caused by the preliminary injunction is not among them.

With all these factors, the decision to be issued by the District Court on the reasoning and evaluation of the 2nd Court of Intellectual and Industrial Property Rights is significant, since this decision will constitute the first court precedent in the pharmaceutical industry for the compensation of damages arising from an unfair preliminary injunction decision.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
Up-coming Events Search
Font Size:
Mondaq on Twitter
Mondaq Free Registration
Gain access to Mondaq global archive of over 375,000 articles covering 200 countries with a personalised News Alert and automatic login on this device.
Mondaq News Alert (some suggested topics and region)
Select Topics
Registration (please scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions